Bristol-Myers Squibb and Harvard partner on fibrosis research

Pharmaceutical Company Product News

Bristol-Myers Squibb has formed a new drug research alliance with the Harvard Fibrosis Network of the Harvard Stem Cell Institute.

The collaboration aims to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. At present, treatments for fibrotic diseases are limited, meaning there is a significant unmet need for new options.

“Bristol-Myers Squibb is partnering with the Harvard Fibrosis Network of the Harvard Stem Cell Institute on a new fibrosis research collaboration.“

It will leverage the capabilities of the Harvard Fibrosis Network, which brings together researchers across the schools and affiliated hospitals of Harvard University, who will work with scientists from Bristol-Myers Squibb on four projects over three years.

Specific focus will be placed on applied fibrosis biology, identification of noninvasive biomarkers, and isolating novel targets for potential anti-fibrotic therapies in the areas of hepatic and cardiac fibrosis.

Dr Carl Decicco, head of discovery at Bristol-Myers Squibb, said: "We are excited to work with the Harvard Fibrosis Network, as we believe this collaboration will advance fibrosis research with a goal of expediting the development of new therapies for patients with these debilitating conditions."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news